A Single-Center, Open-Label, Prospective Study of a 589/1319 nm Dual Wavelength Laser for the Treatment of Facial Hyperpigmentation.

IF 1.5 4区医学 Q3 DERMATOLOGY

Journal of Drugs in Dermatology Pub Date : 2024-11-01 DOI:10.36849/JDD.8196

Suleima Arruda, Alyssa Swearingen, Zahyaa Elmadany, Neil S Sadick

{"title":"A Single-Center, Open-Label, Prospective Study of a 589/1319 nm Dual Wavelength Laser for the Treatment of Facial Hyperpigmentation.","authors":"Suleima Arruda, Alyssa Swearingen, Zahyaa Elmadany, Neil S Sadick","doi":"10.36849/JDD.8196","DOIUrl":null,"url":null,"abstract":"Background: Facial hyperpigmentation, characterized by the excessive production of melanin in the skin, is a prevalent dermatological concern affecting individuals of various ethnic backgrounds.Aims: To evaluate the safety and efficacy of a multi-wavelength 589/1319 nm dual-pulse duration laser device for the treatment of hyperpigmentation Patients/Methods: A total of 17 healthy women (mean [SD] age of 43.4 [11.6] with skin phototype II-IV) were enrolled in this prospective, single-center study. Eligible participants received up to 3 treatments spaced 3 to 5 weeks apart with 2 follow-up visits at 4 and 12 weeks after the final treatment. Assessments included investigator ratings of skin quality, global aesthetic improvement, and hyperpigmentation. Safety and tolerability were monitored throughout the study.Results: Significant improvements in hyperpigmentation and skin quality were observed at the 2 follow-up visits from baseline in most patients per investigator assessments. Patient satisfaction was high, and treatments were safe with transient self-resolving side effects such as erythema.Conclusions: Laser treatments using a dual-wavelength 589/1319nm device significantly improve facial hyperpigmentation in patients of various skin types. J Drugs Dermatol. 2024;23(11):943-947. doi:10.36849/JDD.8196.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/JDD.8196","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Facial hyperpigmentation, characterized by the excessive production of melanin in the skin, is a prevalent dermatological concern affecting individuals of various ethnic backgrounds.

Aims: To evaluate the safety and efficacy of a multi-wavelength 589/1319 nm dual-pulse duration laser device for the treatment of hyperpigmentation Patients/Methods: A total of 17 healthy women (mean [SD] age of 43.4 [11.6] with skin phototype II-IV) were enrolled in this prospective, single-center study. Eligible participants received up to 3 treatments spaced 3 to 5 weeks apart with 2 follow-up visits at 4 and 12 weeks after the final treatment. Assessments included investigator ratings of skin quality, global aesthetic improvement, and hyperpigmentation. Safety and tolerability were monitored throughout the study.

Results: Significant improvements in hyperpigmentation and skin quality were observed at the 2 follow-up visits from baseline in most patients per investigator assessments. Patient satisfaction was high, and treatments were safe with transient self-resolving side effects such as erythema.

Conclusions: Laser treatments using a dual-wavelength 589/1319nm device significantly improve facial hyperpigmentation in patients of various skin types. J Drugs Dermatol. 2024;23(11):943-947. doi:10.36849/JDD.8196.

查看原文本刊更多论文

589/1319 nm 双波长激光治疗面部色素沉着的单中心、开放标签、前瞻性研究。

背景：面部色素沉着的特点是皮肤中黑色素生成过多，是一种普遍存在的皮肤病，影响着不同种族背景的人。目的：评估多波长 589/1319 nm 双脉冲持续时间激光设备治疗色素沉着的安全性和有效性：共有 17 名健康女性（平均 [SD] 年龄为 43.4 [11.6]，皮肤光型为 II-IV）参加了这项前瞻性单中心研究。符合条件的参与者最多可接受 3 次治疗，每次间隔 3 至 5 周，并在最后一次治疗后的 4 周和 12 周进行两次随访。评估包括研究人员对皮肤质量、整体美学改善和色素沉着的评分。在整个研究过程中对安全性和耐受性进行监测：根据研究人员的评估，大多数患者的色素沉着和皮肤质量在两次随访中均较基线有明显改善。患者的满意度很高，治疗很安全，红斑等短暂的副作用可自行缓解：结论：使用波长为 589/1319nm 的双波长设备进行激光治疗可显著改善各种皮肤类型患者的面部色素沉着。J Drugs Dermatol.2024;23(11):943-947. doi:10.36849/JDD.8196.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Drugs in Dermatology DERMATOLOGY-

CiteScore

2.20

自引率

13.30%

发文量

289

审稿时长

3-6 weeks

期刊介绍： The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology. We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality. Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.